The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN).
 
Daniel M. Geynisman
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Exelixis; Merck; Myovant Sciences; Pfizer; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Harpoon therapeutics (Inst); Merck (Inst)
 
Philip Abbosh
Stock and Other Ownership Interests - Abyost PHarmaceuticals
Consulting or Advisory Role - ArTara Therapeutics
Research Funding - Adaptive Biotechnologies; Janssen Oncology (Inst); natera
Patents, Royalties, Other Intellectual Property - Intravesical imidazolium compunds; urine biomarkers patent application
 
Eric A. Ross
Stock and Other Ownership Interests - Procter & Gamble
Patents, Royalties, Other Intellectual Property - Method for Screening Muscle Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy Responsiveness (Inst)
 
Matthew R. Zibelman
Honoraria - Pfizer
Consulting or Advisory Role - AVEO; Blue Earth Diagnostics; EMD Serono; Exelixis; Janssen; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Horizon Pharma (Inst)
Other Relationship - Association of Community Cancer Centers (ACCC)
 
Pooja Ghatalia
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Merck (Inst)
 
Fern Anari
No Relationships to Disclose
 
Katherine Ansel
No Relationships to Disclose
 
James Ryan Mark
No Relationships to Disclose
 
Lambros Stamatakis
Consulting or Advisory Role - Merck
Travel, Accommodations, Expenses - Merck
 
Jean H. Hoffman-Censits
Honoraria - Clovis Oncology; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Foundation medicine; Roche/Genentech; Seagen
Research Funding - Foundation Medicine; Genentech; Genentech; Sanofi
Travel, Accommodations, Expenses - Roche/Genentech
 
Rosalia Viterbo
No Relationships to Disclose
 
Eric M. Horwitz
No Relationships to Disclose
 
Mark A Hallman
Consulting or Advisory Role - New Century Health
 
R. Katherine Alpaugh
No Relationships to Disclose
 
Richard E. Greenberg
No Relationships to Disclose
 
Marc C. Smaldone
No Relationships to Disclose
 
Robert Uzzo
Consulting or Advisory Role - Genentech/Roche; Merck; Pfizer
Speakers' Bureau - Janssen Oncology
Research Funding - Novartis
 
David Chen
Stock and Other Ownership Interests - Pfizer; Pfizer (I)
 
Alexander Kutikov
Leadership - Visible Health
Stock and Other Ownership Interests - Visible Health
Consulting or Advisory Role - Merck; OncoSec; Pfizer; UroToday
Travel, Accommodations, Expenses - Pfizer
 
Elizabeth R. Plimack
Consulting or Advisory Role - AstraZeneca; AVEO; Bristol-Myers Squibb/Medarex; Calithera Biosciences; EMD Serono; Exelixis; IMV; Janssen; Janssen; MEI Pharma; Merck; Pfizer; Regeneron; Seattle Genetics/Astellas; Signatera
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst)